Cargando…

SARS-CoV-2 vaccinations reduce the prevalence of post-COVID Guillain-Barre syndrome

Guillain-Barre Syndrome (GBS) has been repeatedly reported as a neurological complication of COVID-19 (post-COVID GBS [PCG]). Whether the introduction of SARS-CoV-2 vaccines reduced the prevalence of PCG is unknown. This narrative review aimed to compare the number of published PCG cases between the...

Descripción completa

Detalles Bibliográficos
Autores principales: Finsterer, Josef, Matovu, Daniel, Scorza, Fulvio A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9189101/
https://www.ncbi.nlm.nih.gov/pubmed/35751951
http://dx.doi.org/10.1016/j.clinsp.2022.100064
_version_ 1784725509382340608
author Finsterer, Josef
Matovu, Daniel
Scorza, Fulvio A.
author_facet Finsterer, Josef
Matovu, Daniel
Scorza, Fulvio A.
author_sort Finsterer, Josef
collection PubMed
description Guillain-Barre Syndrome (GBS) has been repeatedly reported as a neurological complication of COVID-19 (post-COVID GBS [PCG]). Whether the introduction of SARS-CoV-2 vaccines reduced the prevalence of PCG is unknown. This narrative review aimed to compare the number of published PCG cases between the second half of 2020 (no vaccination available) with those of the first half of 2021 (vaccination available). A total of 124 articles reported 300 patients with PCG between January 2020 and June 2021. The ages ranged from 7 to 94y. There was male dominance. The latency between the onset of COVID-19 and the onset of PCG ranged from -10 to 90d Acute, inflammatory, demyelinating polyneuropathy was diagnosed in 171 patients, acute, motor axonal neuropathy in 24, and acute, motor, and sensory axonal neuropathy in 16 patients. Regarding treatment, 241 patients received immunoglobulins, 28 patients’ plasmaphereses, and 7 patients' steroids. Artificial ventilation was required in 59 patients. Full recovery was achieved in 42 cases, partial recovery in 163 cases, and 17 patients died. The number of published PCG patients fell from 192 in the second half of 2020 to 75 patients in the first half of 2021. It is concluded that the prevalence of PCG has decreased since the introduction of SARS-CoV-2 vaccines. SARS-CoV-2 vaccinations have a positive effect on the prevalence of PCG.
format Online
Article
Text
id pubmed-9189101
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo
record_format MEDLINE/PubMed
spelling pubmed-91891012022-06-13 SARS-CoV-2 vaccinations reduce the prevalence of post-COVID Guillain-Barre syndrome Finsterer, Josef Matovu, Daniel Scorza, Fulvio A. Clinics (Sao Paulo) Review Articles Guillain-Barre Syndrome (GBS) has been repeatedly reported as a neurological complication of COVID-19 (post-COVID GBS [PCG]). Whether the introduction of SARS-CoV-2 vaccines reduced the prevalence of PCG is unknown. This narrative review aimed to compare the number of published PCG cases between the second half of 2020 (no vaccination available) with those of the first half of 2021 (vaccination available). A total of 124 articles reported 300 patients with PCG between January 2020 and June 2021. The ages ranged from 7 to 94y. There was male dominance. The latency between the onset of COVID-19 and the onset of PCG ranged from -10 to 90d Acute, inflammatory, demyelinating polyneuropathy was diagnosed in 171 patients, acute, motor axonal neuropathy in 24, and acute, motor, and sensory axonal neuropathy in 16 patients. Regarding treatment, 241 patients received immunoglobulins, 28 patients’ plasmaphereses, and 7 patients' steroids. Artificial ventilation was required in 59 patients. Full recovery was achieved in 42 cases, partial recovery in 163 cases, and 17 patients died. The number of published PCG patients fell from 192 in the second half of 2020 to 75 patients in the first half of 2021. It is concluded that the prevalence of PCG has decreased since the introduction of SARS-CoV-2 vaccines. SARS-CoV-2 vaccinations have a positive effect on the prevalence of PCG. Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo 2022-06-13 /pmc/articles/PMC9189101/ /pubmed/35751951 http://dx.doi.org/10.1016/j.clinsp.2022.100064 Text en © 2022 Published by Elsevier España, S.L.U. on behalf of HCFMUSP. https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review Articles
Finsterer, Josef
Matovu, Daniel
Scorza, Fulvio A.
SARS-CoV-2 vaccinations reduce the prevalence of post-COVID Guillain-Barre syndrome
title SARS-CoV-2 vaccinations reduce the prevalence of post-COVID Guillain-Barre syndrome
title_full SARS-CoV-2 vaccinations reduce the prevalence of post-COVID Guillain-Barre syndrome
title_fullStr SARS-CoV-2 vaccinations reduce the prevalence of post-COVID Guillain-Barre syndrome
title_full_unstemmed SARS-CoV-2 vaccinations reduce the prevalence of post-COVID Guillain-Barre syndrome
title_short SARS-CoV-2 vaccinations reduce the prevalence of post-COVID Guillain-Barre syndrome
title_sort sars-cov-2 vaccinations reduce the prevalence of post-covid guillain-barre syndrome
topic Review Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9189101/
https://www.ncbi.nlm.nih.gov/pubmed/35751951
http://dx.doi.org/10.1016/j.clinsp.2022.100064
work_keys_str_mv AT finstererjosef sarscov2vaccinationsreducetheprevalenceofpostcovidguillainbarresyndrome
AT matovudaniel sarscov2vaccinationsreducetheprevalenceofpostcovidguillainbarresyndrome
AT scorzafulvioa sarscov2vaccinationsreducetheprevalenceofpostcovidguillainbarresyndrome